Swiss National Bank’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Swiss National Bank’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-104,900	Closed	-$7.89M	–	2728
2022 Q2	$7.89M	Buy	104,900 +5,500	+6%	+$244K	0.01%	1043
2022 Q1	$2.67M	Buy	99,400 +7,100	+8%	+$239K	﹤0.01%	1870
2021 Q4	$4.4M	Hold	92,300	–	–	﹤0.01%	1544
2021 Q3	$6.13M	Buy	92,300 +2,000	+2%	+$142K	﹤0.01%	1317
2021 Q2	$7.04M	Sell	90,300 -3,300	-4%	-$244K	﹤0.01%	1243
2021 Q1	$8.85M	Buy	93,600 +3,600	+4%	+$428K	0.01%	1075
2020 Q4	$11M	Buy	90,000 +13,600	+18%	+$1.49M	0.01%	882
2020 Q3	$6.67M	Buy	76,400 +2,700	+4%	+$188K	0.01%	1003
2020 Q2	$4.76M	Buy	73,700 +38,900	+112%	+$2.24M	﹤0.01%	1175
2020 Q1	$1.55M	Buy	34,800 +500	+1%	+$26.6K	﹤0.01%	1605
2019 Q4	$2.14M	Buy	+34,300	New	+$1.63M	﹤0.01%	1697

Swiss National Bank's TPTX Position: Q3 2022 in Review

Swiss National Bank sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 104,900 shares — an estimated $7.89M sold.

Swiss National Bank first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $11M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Swiss National Bank reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Swiss National Bank sold 104,900 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $7.89M.
Swiss National Bank first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
Swiss National Bank's Turning Point Therapeutics, Inc. Common Stock position peaked at $11M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Swiss National Bank's 13F filing for Q3 2022, filed 9 Nov 2022.